Wei Hong

5PUBLICATIONS
25CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Innate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Aug 17, 2026
Timing of immune checkpoint inhibitor infusion predicts survival in advanced esophageal squamous cell carcinoma: A retrospective cohort study.

|Sep 05, 2025
An Open-Label, Single-Arm, Phase II Trial of Sintilimab Plus Anlotinib for Metastatic Non-Small Cell Lung Cancer After First-Line PD-(L)1 Inhibitor.

Xun Shi, Chen Lin, Lishu Lou

|Apr 22, 2025
Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study.

Jinhui Xue, Yuxiang Ma, Yuanyuan Zhao

|Sep 14, 2024
A narrative review on advances in neoadjuvant immunotherapy for esophageal cancer: Molecular biomarkers and future directions.

Wenjing Wang, Lisha Ye, Huihui Li

|Sep 19, 2023
Sintilimab plus anlotinib as second- or third-line therapy in metastatic non-small cell lung cancer with uncommon epidermal growth factor receptor mutations: A prospective, single-arm, phase II trial.

Kaiyan Chen, Yanjun Xu, Zhiyu Huang

Pageof 1

Frequent Collaborators

2 joint publications

Xiaoling Xu

1 joint publications

Kaiyan Chen

1 joint publications

Xiaoqing Yu

1 joint publications

Hongyang Lu